Phase 1 · Webster, TX
Phase 1 clinical trials in Webster, TX
6 recruiting studies have a site in Webster.
6 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1/Phase 2
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Xencor, Inc.
- Location
- Webster, TX + 27 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingHealthy volunteersPhase 1/Phase 2
First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671
Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics
- Location
- Webster, TX + 2 other US sites
- Eligibility basics
- Ages 25–75
- RecruitingPhase 1
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
Cullinan Therapeutics Inc.
- Location
- Webster, TX + 10 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 1
NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
Merida Biosciences
- Location
- Webster, TX + 10 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection
GigaGen, Inc.
- Location
- Webster, TX + 10 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
Cullinan Therapeutics Inc.
- Location
- Webster, TX + 5 other US sites
- Eligibility basics
- Ages 18+
Who these studies look for
Phase 1 studies often have narrow eligibility: specific age and weight ranges, no recent participation in another study, no nicotine, and limits on medications. Some Phase 1 studies recruit patients rather than healthy volunteers, so check each listing.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.